Livtencity (maribavir) — Point32Health
post-transplant cytomegalovirus (CMV) infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet in adults and pediatric patients (age ≥12 years and weight ≥35 kg)
Initial criteria
- Documented diagnosis of post-transplant cytomegalovirus (CMV) infection/disease
- AND Viral load of CMV DNA is ≥2,730 IU/mL in whole blood or ≥910 IU/mL in plasma
- AND Patient has had treatment failure, intolerance, or confirmed virological resistance to TWO or contraindication to ALL of the following drugs: ganciclovir, valganciclovir, cidofovir, foscarnet
- AND Livtencity is not being used for prevention of CMV infections
Reauthorization criteria
- Documented confirmation that there is no virological resistance to Livtencity (maribavir)
Approval duration
initial 8 weeks; reauthorization 8 weeks; maximum total 16 weeks